BCRT-3, BCRT#1
BIHi001-A
General
Donor Information
General Donor Information |
|
| Sex | male |
| Age of donor (at collection) | neonate |
| Ethnicity | Caucasian, White |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
| Disease associated phenotypes | no phenotypes |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Unknown
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
SNP typing array
|
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA103885930 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
| Provide contact information of the holder of the original Donor Information Sheet: | http://www.lgcstandards-atcc.org/en/Support/LGC_Contact_Us.aspx |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
| If you do not hold the Donor Consent Form, do you know who does? | Yes |
| Contact information / weblink | http://www.lgcstandards-atcc.org/en/Support/LGC_Contact_Us.aspx |
| Alternatives to consent are available? | Yes |
| Alternatives to consent | |
| Alternative consent approval number | |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| How may genetic information associated with the cell line be accessed? | No information |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | No |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
| Source cell line name |
CCD-1112Sk Other names
|
| Source cell type |
Dermal fibroblasts are the major cell type in dermis and are commonly accepted as terminally differentiated cells.
|
| Source cell origin |
A retractable double-layered fold of skin and mucous membrane that covers the glans penis and protects the urinary meatus when the penis is not erect.
Synonyms
|
| Age of donor (at collection) | neonate |
| Source cell line vendor | ATCC |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Genes | |
| Is reprogramming vector detectable? |
No |
| Methods used |
PCR
|
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
EDTA
|
| O2 Concentration | 5 % |
| CO2 Concentration | 5 % |
| Medium |
Essential 8™
|
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|
||||
| SSEA-1 |
No |
|
||||
| SSEA-4 |
Yes |
|||||
| TRA 1-60 |
Yes |
|||||
| POU5F1 (OCT-4) |
Yes |
| Pluripotency Score | Novelty Score | Link to microarray data |
| 31.32 | 1.5 | http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-5145 |
Morphology pictures
Transcriptome Characterisation
Differentiation Potency
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Certificate of Analysis |
|
| Is there a certificate of analysis available? |
Yes
Passage:
|
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46,XY
Karyotyping method:
KaryoLite Bobs
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.